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Introduction
The use of immunosuppressant drugs and also biological
DMARDs in the treatment of juvenile idiopathic arthritis
(JIA) may weaken patient’s immunity and raise the risk of
serious infections, including tuberculosis (TB).
Objectives
To assess the incidence rate of different forms of TB
infection in patients receiving biological treatment of JIA.
Methods
Thirty four children, aged from 3 to 17 years, were
observed prospectively receiving biological treatment for
JIA. Mean disease duration was 5,29 (± 4,24) yrs. Initial
screening for TB included PPD test and chest CT.
Results
Fourteen of 34 patients (41,2%) received toziliaumab
(TOZ), 6 (17,6%) - abatacept (ABA), 4 (11,8%) - etanercept
(ETN), 5 (14,7%) - adalimumab (ADA) and 5 (14,7%) -
infliximab (IFL). Mean treatment duration with biologics
was 16,3 (± 10,47), from 3 to 46 months. Different types of
TB infection were diagnosed in 6 (17,6%) patients while
receiving biological DMARDs. Three of them received
treatment for systemic JIA, 1 - for polyarticular JIA, 1 -
juvenile ankylosing spondylitis and 1- JIA with concomi-
tant uveitis. Different clinical types of TB infection were
observed in these 6 patients: one patient receiving TOZ
developed infiltrative pulmonary TB with dissemination,
two patients (1 on TOZ and 1 on ADA) had primary TB
complex and three (on IFL, ADA, ETN) were diagnosed
with latent TB infection. The common feature TB
infection in all patients receiving biologics was the mildness
of clinical manifestation of the disease.
In addition 3 cases of primary TB complex were
observed in patients with systemic JIA before initiation of
biological DMARD and required prior specific TB therapy.
Conclusion
Children with systemic JIA may be considered to have the
higher risk of different types of TB infection. Treatment
with biological DMARDs (especially with TNF-a and IL-6
inhibitors) also may contribute to TB infection. Regular
TB screening (at least once per 6 months) is required to
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